FDA clearance is a transformative catalyst for CUPR, enabling U.S. commercialization of MEDIFLY Maggots. Monitor for initial sales, partnership announcements, and progress on international registrations in Saudi Arabia, Hong Kong, and China. The dual-species position provides a competitive moat in the niche maggot debridement therapy market.
Price Chart
Executive Summary
Cuprina Holdings announced FDA 510(k) clearance for MEDIFLY Maggots, the first U.S. clearance for a Lucilia cuprina maggot debridement product. This positions the company as the only holder of FDA clearance for both maggot species used in maggot debridement therapy, potentially accelerating U.S. commercialization and regulatory pathways in other markets.
Key Facts
- Cuprina received FDA 510(k) clearance for MEDIFLY Maggots, the first U.S. clearance for a Lucilia cuprina maggot debridement product.
- MEDIFLY Maggots is cleared for debridement of non-healing necrotic skin and soft tissue wounds, including pressure ulcers, neuropathic foot ulcers, and non-healing traumatic or post-surgical wounds.
- Cuprina now holds U.S. FDA commercial rights to both Lucilia sericata (licensed) and Lucilia cuprina (own clearance), a dual-species position no other company holds.
- The clearance was reviewed by FDA's Center for Biologics Evaluation and Research (CBER), which assumed oversight of medicinal maggots in December 2024.
- The company believes the clearance may help accelerate registration pathways in Saudi Arabia, Hong Kong, and mainland China.
Financial Impact
No revenue figures provided; FDA clearance opens U.S. market for MEDIFLY Maggots, creating potential commercial revenue stream for a company with $11M market cap and $3.63M net loss in 2025.
Risk Factors
- Commercialization and market adoption risks for a novel biological therapy in the U.S.
- Uncertainty regarding pace and extent of revenue generation from MEDIFLY Maggots.
- Dependence on regulatory approvals in other target markets (Saudi Arabia, Hong Kong, China) which remain subject to local authorities.
- Prior annual report showed significant net loss and working capital outflows; FDA clearance does not guarantee profitability.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001493152-26-028628 |
| Document: form6-k.htm | 0001493152-26-028628 |
| Document: 0001493152-26-028628-index-headers.html | 0001493152-26-028628 |
| Document: 0001493152-26-028628-index.html | 0001493152-26-028628 |
| Document: 0001493152-26-028628.txt | 0001493152-26-028628 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 6-K | $1.93 $1.85 | ▲ +4.15% | ▲ +4.22% | $1.85 (+4.15%) |
Oct 2, 2026 25d ago | 6-K | $2.42 $1.69 | ▼ −30.17% | ▼ −31.33% | $1.85 (−23.55%) |
Oct 2, 2026 25d ago | Press Release | $2.42 $1.69 | ▼ −30.17% | ▼ −31.33% | $1.85 (−23.55%) |
Sep 29, 2026 28d ago | 6-K | $2.28 $1.99 | ▲ +12.72% | ▲ +14.63% | $1.85 (+18.86%) |
Sep 29, 2026 28d ago | Press Release | $2.28 $1.99 | ▲ +12.72% | ▲ +14.63% | $1.85 (+18.86%) |
Sep 18, 2026 5w ago | 6-K | $1.79 $1.87 | ▼ −4.47% | ▼ −3.20% | $1.85 (−3.35%) |
Sep 17, 2026 5w ago | 6-K | $1.79 $1.87 | ▼ −4.47% | ▼ −3.20% | $1.85 (−3.35%) |
Sep 17, 2026 5w ago | Press Release | $1.79 $1.87 | ▼ −4.47% | ▼ −3.20% | $1.85 (−3.35%) |
Sep 16, 2026 5w ago | 424B4 | $1.60 $1.88 | ▼ −17.50% | ▼ −15.68% | $1.85 (−15.63%) |
Sep 16, 2026 5w ago | EFFECT | $1.60 $1.88 | ▼ −17.50% | ▼ −14.94% | $1.85 (−15.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers